Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cancer-testing company NeoGenomics (NASDAQ: NEO ) is in the midst of a brutal pullback today after announcing it will miss guidance. NEO stock is down more than 30% so far on Tuesday. Source: Shutterstock So wha...
The shares of NeoGenomics (NEO -37.4%) have reached over a three-year low on Tuesday after the operator of cancer testing labs announced the departure of its Chief Executive and pulled its 2022 guidance. Noting the lack of visibility on the company’s prospects after the developmen...
Gainers: IGM Biosciences IGMS +37%. TRxADE HEALTH MEDS +21%. Ginkgo Bioworks DNA +14%. NexImmune NEXI +13%. BioSig Technologies (BSGM) +8%. Losers: NeoGenomics NEO -34%. Progenity PROG -25%. Aveanna Healthcare (AVAH) -21%. Kala Pharmaceuticals...
NeoGenomics (NEO) -29% on Q1 guidance cut; CEO to quit Progenity (PROG) -22% on Q4 earnings release. Stryve Foods (SNAX) -21% releases inaugural shareholder report. Kala Pharmaceuticals (KALA) -19% on Q4 earnings release. Lipocine (LPCN) -15% its partne...
NeoGenomics (NEO) lowered its Q1 revenue outlook, estimating it to be below the low end of its prior guidance of $118M-120M. Consensus estimate is $120.27M. NEO also expects Q1 EBITDA loss to be below the low end of its prior guidance of $15M-12M. The wider-than-expected EBITDA loss was drive...
NeoGenomics (NASDAQ:NEO) said its unit Inivata reported publication of new data for RaDaR liquid biopsy test in patients with early-stage non-small cell lung cancer (NSCLC). In the LUCID study, Inivata's RaDaR minimal residual disease (MRD) and recurrence assay was used to analyze the blood s...
Study further highlights potential of RaDaR to stratify patients and improve treatment outcomes FT. MYERS, FL / ACCESSWIRE / March 17, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, tod...
Wolfe Research is out with its Hits List for short stock ideas taking into account a multitude of factors. The "screen of all screens" identifies the stocks that appear most frequently on the firm's 15 short screens. "Our short screens comprise the 15 most potent valuation, earnings quality, ...
FT MYERS, FL / ACCESSWIRE / March 2, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that senior management will be participating in multiple upcoming institutional investor c...
These are the most used and most widely-adopted cryptocurrencies that are an alternative to traditional payment methods and systems: NEO NEO/USD , Dogecoin DOGE/USD , Cardano ADA/USD , Solana SOL/USD , Avalanche AVAX/USD , and BNB BNB/USD . We are going to go...
News, Short Squeeze, Breakout and More Instantly...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its second quarter 2024 financial results after the close of the U.S. financial markets on Monday, July 29, 2024. Company management will host a webcast and conference call at 4:30 ...
2024-06-23 10:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that Fort Myers’ Mayor, Kevin Anderson, will be dedicating June as NeoGenomics’ Commitment to Cancer Month to honor cancer survivors and those currently living with cancer. Headquartered in...